DrugPatentWatch Database Preview
PROGLYCEM Drug Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Which patents cover Proglycem, and what generic alternatives are available?
Proglycem is a drug marketed by Teva Branded Pharm and is included in two NDAs.
The generic ingredient in PROGLYCEM is diazoxide. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the diazoxide profile page.
Summary for PROGLYCEM
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 83 |
| Clinical Trials: | 4 |
| Patent Applications: | 3,272 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for PROGLYCEM |
| DailyMed Link: | PROGLYCEM at DailyMed |
Recent Clinical Trials for PROGLYCEM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Institutes of Health (NIH) | Phase 2 |
| Albert Einstein College of Medicine, Inc. | Phase 2 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |
Synonyms for PROGLYCEM
| 1342899-70-0 |
| 2270-EP2281815A1 |
| 2270-EP2295550A2 |
| 2270-EP2301933A1 |
| 2270-EP2308838A1 |
| 2270-EP2311827A1 |
| 2H-1,2, 4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide |
| 2H-1,2,4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide |
| 2H-1,2,4-Benzothiadiazine,7-chloro-3-methyl-, 1,1-dioxide |
| 2H-1,4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide |
| 3-methyl-7-chloro-1,2,4-benzothiadiazine 1,1-dioxide |
| 32273-EP2281815A1 |
| 32273-EP2298415A1 |
| 32273-EP2301933A1 |
| 32273-EP2305640A2 |
| 32273-EP2311827A1 |
| 364-98-7 |
| 364D987 |
| 4H-1,2,4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide |
| 7-chloranyl-3-methyl-4H-1$l^{6},2,4-benzothiadiazine 1,1-dioxide |
| 7-chloro-3-methyl-1,2,4-benzothiadiazine,1,1-dioxide |
| 7-Chloro-3-methyl-1lambda~4~,2,4-benzothiadiazin-1-ol 1-oxide |
| 7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide |
| 7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine1,1-dioxide |
| 7-Chloro-3-methyl-2H-1,4-benzothiadiazine 1,1-dioxide |
| 7-chloro-3-methyl-2H-1?^{6},2,4-benzothiadiazine 1,1-dioxide |
| 7-chloro-3-methyl-2H-1$l^{6},2,4-benzothiadiazine 1,1-dioxide |
| 7-chloro-3-methyl-4H-1 |
| 7-chloro-3-methyl-4h-1,2,4-benzothiadiazine 1,1-dioxide |
| 7-chloro-3-methyl-4H-1|E?,2,4-benzothiadiazine-1,1-dione |
| 7-chloro-3-methyl-4H-1$l^{6},2,4-benzothiadiazine 1,1-dioxide |
| 7-chloro-3-methyl-4H-1$l;{6},2,4-benzothiadiazine-1,1-dione |
| 7-chloro-3-methyl-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide |
| 7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido |
| 7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido [Italian] |
| A823275 |
| AC1L1EZN |
| ACM364987 |
| ACN-054388 |
| AKOS015896340 |
| AKOS024458715 |
| AN-23421 |
| AOB5782 |
| Aroglycem |
| B6526 |
| BCP26107 |
| BDBM86248 |
| BG0437 |
| Bio1_000036 |
| Bio1_000525 |
| Bio1_001014 |
| Bio2_000027 |
| Bio2_000507 |
| BPBio1_000016 |
| BRD-K73109821-001-05-2 |
| BRD-K73109821-001-10-2 |
| BSPBio_000014 |
| BSPBio_001307 |
| BSPBio_002290 |
| C-13401 |
| C06949 |
| C8H7ClN2O2S |
| CAS_364-98-7 |
| CAS-364-98-7 |
| CBiol_001750 |
| CC-26456 |
| CCG-101062 |
| CCG-204497 |
| CHEBI:4495 |
| CHEMBL1518123 |
| CHEMBL181 |
| CPD000058392 |
| CS-4745 |
| D 9035 |
| D00294 |
| D5402 |
| DB01119 |
| Diazossido |
| Diazossido [DCIT] |
| Diazossido [Italian] |
| diazoxide |
| Diazoxide (JAN/USP/INN) |
| Diazoxide [USAN:INN:BAN] |
| Diazoxide [USAN:USP:INN:BAN:JAN] |
| Diazoxide, European Pharmacopoeia (EP) Reference Standard |
| Diazoxide, United States Pharmacopeia (USP) Reference Standard |
| Diazoxido |
| Diazoxido [INN-Spanish] |
| Diazoxidum |
| Diazoxidum [INN-Latin] |
| Dizoxide |
| DSSTox_CID_2914 |
| DSSTox_GSID_22914 |
| DSSTox_RID_76786 |
| DTXSID7022914 |
| EINECS 206-668-1 |
| EN300-122611 |
| EU-0100404 |
| Eudemine |
| Eudemine injection |
| FCH1327708 |
| FT-0603087 |
| GDLBFKVLRPITMI-UHFFFAOYSA-N |
| GTPL2409 |
| HMS1361B09 |
| HMS1568A16 |
| HMS1791B09 |
| HMS1922L22 |
| HMS1989B09 |
| HMS2051P20 |
| HMS2089L04 |
| HMS2093N12 |
| HMS2095A16 |
| HMS2234B23 |
| HMS3261A10 |
| HMS3267I11 |
| HMS3371L13 |
| HMS3393P20 |
| HMS3402B09 |
| HMS3712A16 |
| HY-B1140 |
| Hyperstat |
| Hyperstat (TN) |
| Hypertonalum |
| I06-2041 |
| IDI1_033777 |
| KBio2_000027 |
| KBio2_002595 |
| KBio2_005163 |
| KBio3_000053 |
| KBio3_000054 |
| KBio3_001510 |
| KBioGR_000027 |
| KBioGR_001776 |
| KBioSS_000027 |
| KC-115 |
| KS-000010A1 |
| KS-1444 |
| Lopac-D-9035 |
| Lopac0_000404 |
| LP00404 |
| LS-40410 |
| MCULE-5031397425 |
| MFCD00078578 |
| MLS000028459 |
| MLS001076071 |
| MLS001424164 |
| MolPort-003-666-772 |
| MolPort-003-941-186 |
| Mutabase |
| NC00312 |
| NCGC00015380-01 |
| NCGC00015380-02 |
| NCGC00015380-03 |
| NCGC00015380-04 |
| NCGC00015380-05 |
| NCGC00015380-06 |
| NCGC00015380-07 |
| NCGC00015380-08 |
| NCGC00015380-09 |
| NCGC00015380-10 |
| NCGC00015380-11 |
| NCGC00015380-12 |
| NCGC00015380-13 |
| NCGC00022882-03 |
| NCGC00024907-01 |
| NCGC00024907-02 |
| NCGC00024907-03 |
| NCGC00024907-04 |
| NCGC00024907-05 |
| NCGC00024907-06 |
| NCGC00024907-07 |
| NCGC00024907-08 |
| NCGC00261089-01 |
| NSC 64198 |
| NSC 76130 |
| NSC_3019 |
| NSC-64198 |
| NSC-759574 |
| NSC-76130 |
| NSC64198 |
| NSC759574 |
| NSC76130 |
| O5CB12L4FN |
| Opera_ID_608 |
| Pharmakon1600-02300206 |
| Prestwick_163 |
| Prestwick0_000087 |
| Prestwick1_000087 |
| Prestwick2_000087 |
| Prestwick3_000087 |
| Proglicem |
| s4630 |
| SAM001246872 |
| SC-83321 |
| Sch 6783 |
| Sch-6783 |
| SCHEMBL41254 |
| SMR000058392 |
| SPBio_001953 |
| SPECTRUM2300206 |
| Spectrum3_000735 |
| Spectrum4_001248 |
| SR-01000075314 |
| SR-01000075314-1 |
| SR-01000075314-3 |
| SR-01000075314-4 |
| SR-01000075314-6 |
| SRG 95213 |
| SRG-95213 |
| Tocris-0964 |
| Tox21_110132 |
| Tox21_110132_1 |
| Tox21_500404 |
| UNII-O5CB12L4FN |
| VU0239714-6 |
| Z3125 |
| ZINC3872277 |
US Patents and Regulatory Information for PROGLYCEM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Branded Pharm | PROGLYCEM | diazoxide | CAPSULE;ORAL | 017425-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Teva Branded Pharm | PROGLYCEM | diazoxide | CAPSULE;ORAL | 017425-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Teva Branded Pharm | PROGLYCEM | diazoxide | SUSPENSION;ORAL | 017453-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
